AstraZeneca secured exclusive global rights to Dizal Pharmaceuticals’ marketed lung cancer pill Zegfrovy (sunvozertinib) in a deal valued at up to $1.5 billion, tying the acquisition to an FDA and China regulatory push for new indications. Dizal’s oral EGFR exon 20 insertion therapy already has U.S. and China approvals for previously treated NSCLC, and the new licensing package is aimed at expanding into first-line disease.